Past Clinical Trials at OOS

Trials no longer actively enrolling patients:

  • I3Y-MC-JPCW(b) (Eli Lilly)– A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy (NCT number: NCT04752332)